CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Clinical Trials Arena
High ImpactOriginal article

AstraZeneca and Ionis’ stocks drop significantly on Wainua ATTR-CM trial failure

Phase 3negativeWainuaNegative
AI Analysis

Summary

AstraZeneca and Ionis' Wainua failed its Phase 3 ATTR-CM trial, resulting in significant stock price declines for both companies on July 9, 2026.

Clinical Trial Data

Phase

3

Primary Endpoint

Not Met

Outcome Details

ATTR-CM trial failure

Importance:8/10
Sentiment:
-0.95
clinical trial failurestock declineATTR-CMpartnership
Related Companies

Read the original article

Published by Clinical Trials Arena on July 9, 2026 2:28 PM

Read Original